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Abstract
Background
Dietary nitrate supplementation can enhance exercise performance in healthy people, but it
is not clear if it is beneficial in COPD. We investigated the hypotheses that acute nitrate dos-
ing would improve exercise performance and reduce the oxygen cost of submaximal exer-
cise in people with COPD.
Methods
We performed a double-blind, placebo-controlled, cross-over single dose study. Subjects
were randomised to consume either nitrate-rich beetroot juice (containing 12.9mmoles
nitrate) or placebo (nitrate-depleted beetroot juice) 3 hours prior to endurance cycle ergo-
metry, performed at 70% of maximal workload assessed by a prior incremental exercise
test. After a minimum washout period of 7 days the protocol was repeated with the cross-
over beverage.
Results
21 subjects successfully completed the study (age 68±7years; BMI 25.2±5.5kg/m2; FEV1
percentage predicted 50.1±21.6%; peak VO2 18.0±5.9ml/min/kg). Resting diastolic blood
pressure fell significantly with nitrate supplementation compared to placebo (-7±8mmHg
nitrate vs. -1±8mmHg placebo; p = 0.008). Median endurance time did not differ signifi-
cantly; nitrate 5.65 (3.90–10.40) minutes vs. placebo 6.40 (4.01–9.67) minutes (p = 0.50).
However, isotime oxygen consumption (VO2) was lower following nitrate supplementation
(16.6±6.0ml/min/kg nitrate vs. 17.2±6.0ml/min/kg placebo; p = 0.043), and consequently
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nitrate supplementation caused a significant lowering of the amplitude of the VO2-percent-
age isotime curve.
Conclusions
Acute administration of oral nitrate did not enhance endurance exercise performance; how-
ever the observation that beetroot juice caused reduced oxygen consumption at isotime
suggests that further investigation of this treatment approach is warranted, perhaps target-
ing a more hypoxic phenotype.
Trial Registration
ISRCTN Registry ISRCTN66099139
Introduction
Exercise limitation is a common symptom in patients with COPD. While the benefits of sup-
plemental oxygen, at least in non-hypoxaemic subjects, on exercise performance remains
uncertain[1], substantial skeletal muscle hypoxia is observed during exercise in both normal
subjects and COPD patients whose oxygen saturation is maintained by the administration of
supplemental oxygen[2]. Taken together with other data which suggest that anaerobic metabo-
lism is frequent in patients with COPD[3, 4], a potential contributor to exercise limitation in
COPD could be through the mechanism of tissue oxygen delivery, intramuscular oxygen trans-
port or mitochondrial dysfunction. Thus approaches which reduce the oxygen cost of exercise
might be of therapeutic benefit.
Both nutrient and oxygen delivery, as well as mitochondrial function (and thus oxygen con-
sumption), are under regulatory control by the physiological signalling molecule nitric oxide
(NO). NO is produced endogenously by the action of the NO synthase (NOS) family of
enzymes via oxidation of the amino acid L-arginine. NO may also be produced by the reduc-
tion of exogenous dietary nitrate (NO3
-), found at high levels in beetroot and green leafy vege-
tables[5], to nitrite (NO2
-) and then further to NO in a NOS-independent manner[6].
Ingested nitrate is enterally absorbed into the blood, with approximately 25% of the circulat-
ing amount being taken up by the salivary glands (enterosalivary circulation). Nitrate is then
excreted in saliva[7], and reduced from nitrate to nitrite via the nitrate reductase activity of
oral commensal facultative anaerobic bacteria[8]. Salivary nitrite is subsequently swallowed
and may enter the circulation directly as nitrite[8], or be further reduced to NO and absorbed
following oxidation to nitrite or nitrate.
Various studies have reported benefits from dietary nitrate supplementation through the
mechanism of a reduction in the oxygen cost of submaximal exercise in young, healthy individ-
uals[9–13], and this has been associated with improved measures of exercise performance[9–
12, 14]. The majority of studies have used beetroot juice as the nitrate source, the oxygen-spar-
ing effect being dependent largely on nitrate itself since nitrate-depleted beetroot juice fails to
elicit the same effect[11]. This effect has been shown to persist over at least 15 days of continual
supplementation [12].
A beneficial effect of nitrate supplementation has also been demonstrated during exercise in
hypoxic conditions[15], which is of interest for people with chronic respiratory disease. Two
early studies suggested benefit in patients with COPD [16, 17], although both studies were
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limited by the placebo preparation selected, and other groups have failed to reproduce these
findings using a robust placebo[18, 19]. However, in the two latter studies the dose of nitrate
administered immediately prior to testing was below that which has been shown in health to
induce improvement in exercise performance[6], and in one case testing was performed only
one hour post dosing[19] when nitrite levels may not yet have peaked. Thus these findings
need further investigation with a higher dosing regimen given at an appropriate time interval
prior to exercise testing, particularly since the studies failed to show any effect on blood pres-
sure[18, 19]. The aim of this study was to investigate the effects of a higher dosing regimen of
nitrate, in the form of beetroot juice, on exercise performance in COPD with concomitant mea-
surements of pulmonary oxygen uptake and with comparison to a robust placebo preparation.
Materials and Methods
Patient selection
All participants provided written informed consent prior to enrolment in the study, which was
approved by the Bromley Research Ethics Committee (reference 13/LO/0372) and conducted
in line with the principles of the Declaration of Helsinki. COPD patients of GOLD stage II-IV
[20] were considered for inclusion and recruited through outpatient clinics at the Royal
Brompton Hospital and through public outreach events including World COPD Day. Recruit-
ment started on 24th June 2013 and was completed on 28th April 2014, with follow-up com-
pleted on 3rd June 2014. This study was registered prospectively on a publicly accessible
database (www.iscrn.com/ISRCTN66099139). The authors confirm that all ongoing and
related trials for this intervention are registered.
Exclusion criteria for the study included patients taking nitrate-based medications or phos-
phodiesterase V inhibitors, those with other medical conditions likely to benefit from nitrate
supplementation (including ischaemic heart disease and peripheral vascular disease), and
patients on long-term oxygen therapy or antibiotic therapy (whether on an acute or prophylac-
tic basis). Those patients considered clinically unstable (within one month of pulmonary
exacerbation) or suffering from hypotension or significant renal impairment (eGFR<50ml/
min/1.73m2) were also excluded from the study.
Study design and randomisation
The study was a double-blind, cross-over, placebo-controlled trial. Allocation of the order of
beverages was performed using a computer-generated randomisation in blocks of 4, produced
by an independent statistician with consecutive numbers linked to preparations of placebo or
active treatment. The researcher responsible for enrolment and outcome measurements
remained separate from the randomisation process and remained blinded throughout the
study and during data analysis. The principal investigator who was not involved in any patient
visits held the randomisation list and indicated the patient assignment order.
We hypothesised that nitrate supplementation would increase time to exhaustion during
symptom-limited cycle ergometry at 70% peak workload as assessed previously using an incre-
mental, maximal, symptom-limited cardiopulmonary exercise test. Secondary outcome mea-
sures included plasma nitrate and nitrite levels, blood pressure response, area under the VO2
curve to isotime, and plasma metabolomics.
Intervention
140ml of BEET-IT Sport Stamina Shot (James White Drinks, Ipswich, UK) containing 0.8g
nitrate and 140ml of a matched placebo of beetroot juice specifically depleted of nitrate were
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used as the active and placebo preparations, respectively. The placebo preparation was identical
in appearance and taste[11], and also produced beeturia. The dose chosen was intended to pro-
vide a bolus of nitrate (12.9mmoles) exceeding that necessary to reduce oxygen consumption
during submaximal exercise in young healthy subjects[6], and was selected as a convenient
dosing method (2x 70ml bottles) which was readily acceptable and easily ingested.
Subjects were requested to avoid foods naturally high in nitrate in the 48hour period prior
to the dosing visit and were asked to match food and caffeine consumption on the two days of
testing. Subjects were additionally asked to avoid use of mouthwash and chewing gum in the
48hour period prior to testing as this has previously been shown to reduce oral bacterial nitrate
reductase activity[21]. Subjects were also advised to avoid heavy exercise in the 24 hours prior
to each dosing visit.
Study conduct
All data were collected at the NIHR Respiratory Biomedical Research Unit at the Royal Bromp-
ton and Harefield NHS Foundation Trust. Following successful screening the subjects attended
for measurement of baseline characteristics during which several parameters were recorded
including vital signs, anthropometric and bioimpedance measurements, quality of life assess-
ment, full pulmonary function testing, quadriceps maximal volitional contraction, physical
activity monitoring, and an incremental maximal symptom-limited cycle ergometry test was
performed.
On the dosing visits the subjects attended on the day of testing in the morning; after a 10 min-
ute rest period blood pressure measurements and baseline plasma samples were obtained, after
which the patients were dosed. 3 hours later both blood pressure measures and blood sampling
was repeated prior to endurance cycle ergometry at a constant work rate (70% peak workload
achieved on prior maximal incremental exercise testing). The cycle test was conducted at the
same time on each occasion. Further blood draws were taken at peak exercise. After a minimum
wash-out period of 7 days the protocol was repeated with the crossover beverage.
Blood pressure, anthropometrics and fat fee mass measurements
Blood pressure was measured using an automated blood pressure monitor (Omron M6,
Omron Healthcare Europe, Hoofddorp, Netherlands). Measurements were performed in the
seated position with the subject’s arm supported. A mean of three measurements was recorded.
Height (cm) without shoes was measured using a wall mounted measure, and weight (kg) mea-
sured using standardised scales.
Fat free mass (FFM) was determined using bioelectrical impedance analysis by measuring
the electrical resistance between the wrist and ankle using a Bodystat 4000 device (Bodystat,
Isle of Man, UK). Subjects lay supine for 10 minutes prior to measurement. Electrodes were
placed on the dominant hand and foot, at 2cm proximal to the carpometacarpal joint and the
ulnar level of the wrist on the dorsal aspect of the hand, and at 2cm proximal to the carpometa-
tarsal joint and level of the malleoli of the ankle respectively. The value obtained is dependent
on body water content and based on this FFM can be calculated using a disease specific regres-
sion equation[22]. Fat Free Mass Index (FFMI) was calculated by dividing FFM by height in
metres squared (kg/m2). Individuals with a FFMI below 16 kg/m2 in males and 15 kg/m2 in
females were considered to have evidence of FFM depletion[22].
Physical activity measurement
Patients were asked to wear a physical activity monitor (SenseWear Pro Armband, Bodymedia,
Pittsburg, USA) continually for a week that incorporates a biaxial accelerometer and energy
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expenditure measurements[23]. The armband was placed over the body of the triceps muscle
of the right arm and the subject asked to wear it continuously except when bathing. Data was
analysed over a period of 5 days including 2 weekend days.
Quadriceps strength
Maximum isometric quadriceps force (QMVC) was measured using the technique of Edwards
et al.[24]. Prior to each measurement calibration was performed using a standardised weight.
Subjects were seated with the leg flexed at an angle of 90° relative to the edge of the couch. The
right leg was tested unless it was not feasible to do so. An inextensible strap was placed around
the subject’s ankle and connected to a strain gauge. The maximum force generated and sus-
tained for at least 1 second during at least five contractions with vigorous encouragement was
measured (recorded in kg). A minimum of 30 seconds was allowed between each effort. Output
from the strain gauge was processed as a digital output by a Powerlab recording unit and ana-
lysed using LabChart software (AD Instruments, Oxfordshire, UK) sampling at 10kHz. The
percentage predicted QMVC was determined according to regression equations based on age,
gender and FFM[24, 25].
Pulmonary function testing
Measurements were made in the lung function department of the Royal Brompton Hospital
according to international guidelines and with rigorous quality assurance in place with a Jaeger
master lab system (CompactLab system, Jaeger, Wurzburg, Germany). Spirometry, gas transfer
and plethysmographic lung volumes were also measured in accordance with European Respi-
ratory Society (ERS)/ American Thoracic Society (ATS) guidelines[26–28]. Standardised lung
function testing reference equations were based on the European Coal and Steel Community
(ECSC) reference values[29]. Capillary blood gas samples were taken at rest.
Health-related quality of life measures
Subjects completed the St George Respiratory Questionnaire for COPD patients (SGRQ-C)
and the COPD Assessment Test (CAT). Each is validated in assessing health-related quality of
life in COPD [30, 31].
Cycle ergometry testing
A symptom limited incremental exercise test was performed at baseline on a bicycle ergometer
(Ergoselect 100, Ergoline, Bitz, Germany) with metabolic measurements collected using a
mouthpiece (Masterscreen CPX metabolic cart, CareFusion, Basingstoke, UK) and analysed
using JLAB software (JLAB Lab Manager version 5.32, Jaeger, CareFusion, Basingstoke, UK).
Following a 2 minute rest period and 2 minute free cycling workload increased by 5 Watts
every 30 seconds with subjects being asked to maintain a speed of 60–70 revolutions per min-
ute. Measurements were taken of peak workload, VO2, VCO2, minute ventilation, respiratory
rate and tidal volume. Peak workload was defined as the greatest workload that the subject was
able to maintain for a 30 second period.
To evaluate the effects of the intervention on cardiorespiratory fitness and skeletal muscle
function endurance cycle ergometry testing was performed 3 hours following dosing at 70%
peak workload achieved on incremental cycle ergometry. The endurance time was calculated as
the time from the beginning of loaded cycling to the point of test cessation due to symptom
limitation. Breath-by-breath data was obtained and rolling 8-breath averages were used in the
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isotime analysis (with isotime being defined as the duration of the shorter of the two exercise
tests).
Plasma nitrate/nitrite analysis
All plasma samples (baseline, 3 hours post dosing and peak exercise) were obtained by venesec-
tion in lithium heparin tubes and immediately spun for 10 minutes at 520g at 4°C. The result-
ing supernatant was pipetted into 2ml polypropylene cryotubes, taking care to avoid any
contamination from the buffy coat containing the white cells/ platelets atop the erythrocyte
pellet, and immediately frozen at -80°C.
Nitrate and nitrite plasma levels were assessed using a post-column diazo coupling reaction
(Griess reaction) in combination with high-performance liquid chromatography (HPLC)
(Eicom NOx analyser, ENO-20, San Diego, USA)[32]. Nitrate and nitrite were first separated
on the analytical column. Nitrite then reacts with the Griess reagent generating a red diazo
compound, the absorbance of which was measured at 540nm using a spectrophotometric
detector. Nitrate passing through the on-line reduction column was reduced to nitrite before
undergoing the same diazo coupling reaction. The peak areas of absorption of solutions of
know standard concentrations were then compared to those produced by the test samples to
provide measures of plasma nitrate and nitrite.
Plasma nuclear magnetic resonance spectroscopy analysis
Plasma samples were defrosted at room temperature and centrifuged at 16,000g for 10 minutes.
An aliquot of 300μl was then mixed with 300μl of NMR buffer (double distilled water contain-
ing 8% deuterium oxide (D2O) for the magnetic lock). The resulting mixture was transferred to
5mm NMR tubes within a 96-tube rack. 1H-NMR spectra of plasma samples were obtained
using a Bruker Avance III 700 MHz spectrometer (Bruker Biospin, Karlsruhe, Germany) at the
operating 1H frequency 700.2 MHz with a temperature of 298K. A Carr-Purcell-Meiboom-Gill
(CPMG) pulse sequence (Bruker experiment: cpmgpr1d) was applied to better visualise low
molecular weight metabolites. A spin relaxation delay of 76ms was used and a total of 32 scans
were acquired.
Spectra were processed and analysed as described previously[33]. An exponential window
function was applied with a line broadening of 0.3 Hz prior to Fourier transformation. All
chemical shifts were manually referenced to formate (δ = 8.44 ppm).
Data analysis and statistics
We studied a convenience sample of 25, offering a good chance of identifying a clinically mean-
ingful effect. Data are presented as mean ± standard deviation and were analysed using Graph-
Pad Prism version 5.0 for Windows (GraphPad Software, San Diego, California, USA).
Repeated measures analysis of variance (ANOVA) was utilised to compare plasma nitrate
metabolites between treatment conditions and at each specific time-point. To compare oxygen
consumption between study conditions, individual cardiopulmonary exercise test data periods
were expressed as percentiles of isotime (the duration of the shorter of the two tests) and the
individual responses grouped to allow analysis of VO2 against percentage of isotime (plotted at
the midpoint of each 10th percentile of isotime). The area under this curve was assessed for
each subject and the two conditions, then compared using a paired t-test. Resting and isotime
measurements between treatment conditions were compared using paired t-tests, or the appro-
priate non-parametric test for data that was not normally distributed. A p-value<0.05 was
considered to be statistically significant.
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Results
Subjects
25 patients were enrolled into the study, of whom 21 completed the full study protocol (Fig 1).
Recruitment started in June 2013 and the trial completed in June 2014 when the 25 enrolled
patients had either completed or been withdrawn. The baseline characteristics of the partici-
pants are presented in Table 1. Patients were 100% compliant with the dosing protocol with no
adverse effects noted except beeturia.
Venous nitrate and nitrite measures
Venous plasma nitrate measurements at all timepoints are shown in Fig 2. Following dosing
with nitrate-rich beetroot juice plasma nitrate levels increased substantially (37.0 ± 16.4μM
baseline vs. 820.2 ± 187.7μM post dosing; p<0.0001) and remained significantly elevated at
peak exercise (917.1 ± 291.6μM; p<0.0001). There were no significant changes in plasma
nitrate concentrations following dosing with the placebo preparation (45.7 ± 15.8μM baseline
vs. 45.3 ± 16.5μM post dosing; p>0.99). Plasma nitrite levels were below the quantifiable limit
(0.2μM) in all but three patients at baseline and remained so in the placebo condition but
increased following nitrate supplementation to 1.57 ± 0.98μM and remained elevated at peak
exercise (1.37 ± 0.65μM).
Endurance exercise time
The median endurance time during cycle ergometry performed at 70% maximum workload
was not significantly different between the treatment groups (5.65 (3.90–10.40) nitrate vs. 6.40
Fig 1. CONSORT recruitment diagram for enrolment and study completion.
doi:10.1371/journal.pone.0144504.g001
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(4.01–9.67) minutes placebo; p = 0.50). The individual responses are depicted in Fig 3. We also
tested for an order effect, but none was present (the change in endurance time if nitrate supple-
mentation was applied first was -2.03±4.64 minutes, compared to 1.92±4.16 minutes if placebo
was administered first; p = 0.13).
Blood pressure responses
The changes in resting blood pressure parameters following ingestion of nitrate-rich beetroot
juice and placebo are shown in Fig 4. The reduction in systolic blood pressure after dosing
between treatment conditions was not significantly different, however, the reduction in dia-
stolic blood pressure was greater in the nitrate supplemented group (7±8 nitrate vs. 1±8mmHg
placebo; p = 0.008). There was a trend towards greater lowering of the mean arterial pressure
following nitrate supplementation, although this was not statistically significant (7±8 nitrate
vs. 3±8mmHg placebo; p = 0.07).
Table 1. Demographic and baseline clinical characteristics of the subjects (n = 21).
Measurement Mean (SD)
Sex (♂:♀) 16:5
Age (years) 68 (7)
Systolic BP (mm Hg) 137 (19)
Diastolic BP (mm Hg) 79 (7)
Smoking PYH 40 (29)
MRC dyspnoea score 2 (1)
CAT score 14 (7)
SGRQ-C total 35.37 (13.00)
BMI (kg/m2) 25.2 (5.5)
FFM (kg) 48.9 (8.4)
FFMI (kg/m2) 16.9 (2.2)
QMVC (kg) 37.8 (10.7)
QMVC % predicted 87.8 (19.3)
Average daily step count 6669 (4436)
Average PAL 1.50 (0.20)
FEV1 (L) 1.33 (0.58)
FEV1% predicted 50.1 (21.6)
TLCOc % predicted 54.1 (19.3)
RV % predicted 167 (53)
TLC % predicted 119 (14)
RV/TLC ratio (%) 52.3 (8.7)
PaO2 (kPa) 10.7 (1.2)
Peak power on cycle (watts) 71.9 (30.8)
Peak VO2 (ml/min/kg) 18.0 (5.9)
Data shown are mean (SD). Abbreviations: BP–blood pressure; PYH–pack year history; MRC–Medical
Research Council; CAT–COPD assessment test; SQRC-C–St. George’s respiratory questionnaire for
COPD; BMI–body mass index; FFMI–fat free mass index; QMVC–quadriceps maximal volitional
contraction; PAL- physical activity level; FEV1 –forced expiratory volume in 1 second; TLCOc−carbon
monoxide diffusing capacity; RV–residual volume; TLC–total lung capacity; VO2 –pulmonary oxygen
uptake.
doi:10.1371/journal.pone.0144504.t001
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VO2 curves to isotime
At rest there was no significant difference in minute ventilation or VO2 following dosing with
either nitrate-rich beetroot juice or placebo (Table 2). At isotime (i.e. the longest time of
Fig 2. Alterations in plasma nitrate following dosing. Plasma nitrate concentrations prior to (‘baseline’)
and following consumption of a nitrate-rich or placebo beverage. ‘Post dosing’ indicates a time point 3 hours
following consumption which was immediately prior to cardiopulmonary exercise testing. ‘Peak’was a time
point at the point of exhaustion during endurance cycle ergometry testing. Repeated measures analysis of
variance (ANOVA) was used to compare plasma nitrate metabolites between treatment conditions and at
each specific time-point; *significantly different from baseline, p<0.0001; †significantly different from placebo
group, p<0.0001.
doi:10.1371/journal.pone.0144504.g002
Fig 3. Endurance time during cycle ergometry at 70%maximal workloadmeasured in the placebo and
nitrate-rich beetroot juice dosing conditions. AWilcoxon test was used to compare median values in the
two treatment groups; no significant difference was found.
doi:10.1371/journal.pone.0144504.g003
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equivalent exercise completed under either study condition) both pulmonary VO2 and minute
ventilation were lower in the nitrate supplemented condition than placebo (Table 2). There
Fig 4. Blood pressure parameters following dosing. Alterations in blood pressure parameters (systolic
blood pressure sBP, diastolic blood pressure dBP and mean arterial pressure MAP) relative to
presupplemented baseline 3 hours following dosing with nitrate-rich beetroot juice or placebo preparation.
Paired t-tests were used to compare blood pressure parameters between treatment groups; *significantly
different from placebo, p<0.01.
doi:10.1371/journal.pone.0144504.g004
Table 2. Rest and isotime analysis of the cardiopulmonary exercise test parameters.
Parameter Timepoint Placebo Nitrate-rich beetroot juice Difference p value
HR (bpm) Rest 85 (11) 87 (11) 2 (7) 0.063
HR (bpm) Isotime 122 (17) 121 (20) -1 (10) 0.30
BF (breaths/min) Rest 16 (4) 17 (4) 1 (3) 0.095
BF (breaths/min) Isotime 32 (8) 32 (5) 0 (7) 0.48
VT (L) Rest 0.93 (0.43) 0.87 (0.25) -0.06 (0.26) 0.33
VT (L) Isotime 1.44 (0.39) 1.40 (0.47) -0.04 (0.18) 0.12
VE (L/min) Rest 13.27 (3.90) 13.37 (3.95) 0.10 (2.29) 0.34
VE (L/min) Isotime 43.85 (13.94) 41.88 (14.85) -1.97 (4.52) 0.029*
VO2 (ml/min/kg) Rest 4.5 (1.2) 4.4 (1.3) -0.1 (0.9) 0.32
VO2 (ml/min/kg) Isotime 17.2 (6.0) 16.6 (6.0) -0.6 (1.48) 0.043*
VCO2 (ml/min/kg) Rest 4.2 (1.2) 4.2 (1.3) 0.0 (0.82) 0.49
VCO2 (ml/min/kg) Isotime 17.1 (6.0) 16.7 (6.3) -0.4 (1.74) 0.14
Power/VO2 ratio (W/ml/min/kg) Isotime 2.92 (0.73) 3.03 (0.73) 0.11 (0.29) 0.053
SpO2 (%) Rest 95 (2) 96 (2) 0 (2) 0.26
SpO2 (%) Isotime 92 (4) 93 (4) 1 (2) 0.15
Oxygen pulse (ml/beat) Rest 3.8 (1.0) 3.6 (0.9) -0.2 (0.69) 0.12
Oxygen pulse (ml/beat) Isotime 10.0 (2.6) 9.7 (2.3) -0.3 (1.2) 0.09
Relative oxygen pulse (ml/beat/kg) Rest 0.053 (0.0138) 0.051 (0.014) -0.002 (0.010) 0.15
Relative oxygen pulse (ml/beat/kg) Isotime 0.143 (0.039) 0.138 (0.036) -0.005 (0.014) 0.043*
Data are shown as mean (SD)
*p<0.05.
Abbreviations: HR—heart rate; BF–breathing frequency; VT–tidal volume; VE–minute ventilation; VO2 –pulmonary oxygen uptake; VCO2—exhaled carbon
dioxide production; SpO2 –peripheral arterial oxygen saturation.
doi:10.1371/journal.pone.0144504.t002
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was a numerical improvement in the power/VO2 relationship (P/O ratio) in the nitrate supple-
mented condition, although this was not statistically significant.
VO2 curves to isotime revealed a significant separation of the curves between the two treat-
ment conditions (Fig 5). The area under the curve to VO2 isotime was also calculated for each
subject to enable a comparison of the two treatment conditions (Fig 6).
Plasma NMR spectroscopy analysis
Exercise related plasma metabolites showed no difference when comparing pre and peak exer-
cise values under the two treatment conditions (Fig 7).
Discussion
Our trial, in patients with COPD, failed to demonstrate an improvement in endurance exercise
performance following acute nitrate dosing in the form of beetroot juice. However, nitrate sup-
plementation was biologically active, causing reductions in resting diastolic blood pressure and
oxygen consumption at isotime during exercise, which may warrant further investigation.
Fig 5. Isotime VO2 analysis. The graph represents the VO2 at each 10
th percentile of isotime with 0% representing the initiation of loaded cycling at 70%
maximal workload achieved on incremental cycle ergometry. The area under the curves to isotime was compared using a paired t-test showing significant
separation of the curves representing the two treatment conditions (p = 0.027).
doi:10.1371/journal.pone.0144504.g005
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Critique of the method
Adequate nitrate supplementation was confirmed by the observation of a 22-fold rise in plasma
nitrate within 3 hours. Baseline plasma nitrate levels were similar to those of young recreation-
ally active individuals[6, 34] and, whilst we were concerned that possible age related changes in
Fig 6. Individual responses for area under the curve (AUC) to VO2 isotime. There was a significant
difference between the two treatment conditions with a reduction in the area of the curve to VO2 isotime in the
nitrate supplemented condition.
doi:10.1371/journal.pone.0144504.g006
Fig 7. Alteration in plasmametabolomics during endurance cycle ergometry. Values are expressed as
a ratio of peak exercise:pre exercise, with a value of 1 indicative of no change. Paired t-tests were utilised to
compare metabolite levels between treatment conditions, with no significant difference seen for any
metabolite analysed.
doi:10.1371/journal.pone.0144504.g007
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digestion, enterosalivary circulation and oral commensal bacteria might impair nitrate delivery,
the plasma nitrate levels achieved exceeded even those achieved by administration of a higher
dose of nitrate in healthy young individuals[6]. Secondly, we observed a statistically significant
reduction in diastolic blood pressure as previously noted in healthy individuals[35, 36], seniors
with peripheral vascular disease[37], and COPD patients[16, 17]. One previous study has failed
to show a reduction in blood pressure parameters following acute nitrate dosing in COPD[18].
However that study, which also failed to show an effect on exercise performance, used a lower
treatment dose of nitrate and achieved plasma nitrate levels that were 4-fold lower than our
dosing regimen (215±84μM vs. 820±288μM). Previous work has established that both reduc-
tion in blood pressure and post-dose plasma nitrate levels are dose-dependent[6]. Thus an
important conclusion of the current study is that a single higher dose of nitrate is both safe and
biologically active in COPD.
The plasma nitrite levels fell below the limit of quantifiability in the majority of baseline
samples. Part of the explanation for this, besides a small interfering peak apparently originating
from the beetroot juice, is that samples were not pre-treated with a thiol-blocking agent prior
to centrifugation; such treatment ensures there is no flux of nitrite across blood cell mem-
branes, which may lower plasma concentrations. However, high levels of plasma nitrite were
readily measurable following nitrate dosing.
We failed to observe an improvement in exercise performance following nitrate dosing,
despite a reduction in the oxygen cost of exercise. There are several possible explanations for
this. Firstly, this could be due to statistical power and variation in endurance time. The variabil-
ity in endurance time at 70% maximal workload on endurance cycle ergometry was beyond
what we have observed in previous studies in a similar population[38]. In part this may be
explained by day-to-day symptom variability in COPD[39], and might thus be an expected fea-
ture of studies in this condition using this outcome measure as has been reported by other
groups studying nitrate supplementation in COPD[16, 17, 19]. A trial run might have reduced
this variability, although it is important to note no order effect was identified. Studies using
cycle ergometry methodology and agents of proven efficacy (for example bronchodilators)
have tended to have larger sample sizes than ours[38, 40, 41]. Certainly, significant caution is
needed when interpreting the results of non-blinded studies in this field, and emphasises the
importance of using nitrate-depleted beetroot juice (which also causes beeturia) as a placebo
[16, 17].
Secondly, it may simply be the case that this small improvement in the oxygen cost of exer-
cise does not impact on the rate limiting parameters in exercise in ventilatory limited patients.
Thirdly, we may have studied the wrong patient group. By design we did not include patients
on oxygen supplementation but it may be the case that it is this specific patient phenotype
where a reduction in the oxygen cost of exercise produces the greatest benefit.
Significance of the findings
While it is possible that a larger sample size might have given a positive result this seems rela-
tively unlikely given exercise time was also numerically shorter in the treatment group. How-
ever, the observation (confirmed by the fall in blood pressure) that nitrate supplementation is
biologically active and associated with a measurable reduction in oxygen consumption is of
interest. Cardiovascular comorbidities are common in patients with COPD, so an intervention
that lowers blood pressure may produce clinical benefit outside of a direct effect on exercise
performance.
Some prior data are available regarding nitrate supplementation with beetroot juice in
COPD. An improvement in endurance cycle ergometry exercise time has been previously
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noted in a randomised cross-over study[16]. However, we believe that caution is needed in
interpreting this result, partly because a matching placebo beverage (i.e. one which caused bee-
turia) was not used. This study as noted by the authors, also noted inter-individual variability
in endurance time despite the use of a familiarisation constant work rate exercise test, and
appropriate adjustment if the endurance time was outside of the 4–10 minute range. In fact,
some individual responses were of a greater magnitude than could be explained by a plausible
biological mechanism, thus skewing the overall data for endurance time. Despite this, in line
with our own study, a similar reduction in pulmonary oxygen uptake at isotime was noted (of
the order of 0.7ml/min/kg), although this failed to reach statistical significance (p = 0.099)
most likely due to under-powering[16]. This lends support to our own findings regarding the
influence of nitrate supplementation on the oxygen cost of exercise.
Two further studies in COPD (both reported after we started our study) used a robust pla-
cebo but either failed to show a positive effect on oxygen consumption[18] or did not measure
this variable[19], and both showed no improvement in exercise performance[18, 19]. Effects
on oxygen consumption have previously been shown to be dose-dependent[6], and thus these
negative findings may be due to the use of an insufficient dose of nitrate. Consideration should
also be given to the fact that there are recognised ‘responders’ and ‘non-responders’ to nitrate
supplementation when studying athletic populations[42, 43]. Whilst the lack of response in
elite athletes may in part be explained by intrinsic high levels of nitrate metabolites through
both exercise induced upregulation of NOS activity[44] and the selection of a diet rich in
nitrate, the fact that within that group there is variability in response indicates that other unrec-
ognised factors are likely at play[42, 43]. Our own study is too small to enable effective subana-
lysis but it should remain a focus of future studies to consider factors that may affect
responsivity to nitrate loading, allowing those subjects most likely to benefit from nitrate sup-
plementation to be both recognised and targeted.
The reduction of VO2 at absolute isotime in our study is of a similar magnitude (3–4%) to
that recorded in healthy individuals[6]. The cause of this observation is unclear, but of interest.
Several potential modes of action of nitrate have been proposed including alterations to skeletal
muscle blood flow[45], improved efficiency of the mitochondrial oxidative phosphorylation
[46], effects on energy requiring processes in skeletal muscle[47, 48], alterations to mitochon-
drial biogenesis[49], blood viscosity[50] and NOS substrate availability[51]. No significant
changes were noted in any of the metabolites identified in the NMR spectroscopy array, and
although lactate rose appropriately following the exercise challenge this was of equal magni-
tude in both conditions, suggesting, as in health, that nitrate does not promote anaerobic
metabolism[9].
Use of phosphorus-31 NMR spectroscopy have suggested that nitrate supplementation acts,
at least in part, via reduced ATP cost of muscle force production[9]. Separately we have
recently demonstrated a trend towards longer ADP recovery times in COPD patients prese-
lected for quadriceps dysfunction[3]. The generation of ATP is dependent on the generation
and maintenance of the electrochemical proton gradient. However, not all of this membrane
potential is eventually coupled to ATP production due to proton leakage across the inner mito-
chondrial membrane, through uncoupling proteins and the adenine nucleotide translocase.
Larsen et al.[46] demonstrated ex vivo that following 3 days of nitrate supplementation har-
vested human skeletal muscle mitochondria increased oxidative phosphorylation efficiency,
correlating with a 3% reduction in whole-body oxygen consumption during submaximal work-
load exercise[46]. Future studies are clearly required to inform the mechanistic action of nitrate
to allow the exploration of pharmacological therapies that may exploit the relevant pathways.
Although our data do not support a role for general use of nitrate supplementation using
beetroot juice in this setting we believe, because of the observation of reduced oxygen
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consumption, that targeting specific phenotypes in COPD may lead to the identification of
therapeutic benefits. Thus, for example, we are now conducting a trial to investigate nitrate
supplementation as an adjunct to pulmonary rehabilitation (www.controlled-trials.com/
ISRCTN27860457), powered to detect an improvement in incremental shuttle walking dis-
tance. Other possible feasibility studies could be those in patients stratified for lactataemia
(indicating anaerobic metabolism) during exercise, or those with either systemic or marked
local hypoxia (for example detected using near-infrared spectroscopy[2]).
In conclusion, acute administration of 0.8g nitrate in the form of beetroot juice failed to
improve endurance exercise cycle capacity compared with placebo, but the reduction in oxygen
consumption during exercise in COPD subjects and the reduction observed in resting diastolic
blood pressure confirm a biological action at this dose. Several studies have now confirmed the
blood-pressuring lowering properties of nitrate administered as beetroot juice in COPD, and as
comorbidities are common in this population this may be an important effect. Since the inter-
vention is safe and inexpensive further studies are warranted to establish whether it has a thera-
peutic role in specific COPD phenotypes.
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